AZNAstraZenecaRunning, no new patients
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Metastatic Castration-resistant Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 110 (final count)
- Started
- Jun 24, 2021
- Main results expected
- Jan 22, 2024
- Fully finished
- Feb 5, 2027
- Results posted
- Jun 29, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiological Progression Free Survival (rPFS)
Measured over: Tumour imaging CT/MRI and bone scan were assessed every 8 weeks from randomisation to week 24 and then every 12 weeks until RECIST progression. Patients were followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05171816 · record last updated 2026-08-28 · checked 2026-11-09 15:47 UTC